

RealRate

PHARMACEUTICAL 2021











PHARMACEUTICAL 2021



## RealRate

Actinium Pharmaceuticals Inc. Rank 64 of 402

The relative strengths and weaknesses of Actinium Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Actinium Pharmaceuticals Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 87% points. The greatest weakness of Actinium Pharmaceuticals Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 18% points.

The company's Economic Capital Ratio, given in the ranking table, is 233%, being 186% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	64,925
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	4,767
Liabilities, Non-Current	0
Other Assets	1,160
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	311
Other Net Income	178
Other Revenues	0
Property and Equipment	312
Research and Development	16,085
Selling, General and Administrative Expense	6,308

Output Variable	Value in 1000 USD
Assets	66,397
Liabilities	5,078
Expenses	22,393
Revenues	0
Stockholders Equity	61,319
Net Income	-22,215
Comprehensive Net Income	-22,215
Economic Capital Ratio	233%

